These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27044078)

  • 1. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.
    Willis JR; Finn JA; Briney B; Sapparapu G; Singh V; King H; LaBranche CC; Montefiori DC; Meiler J; Crowe JE
    Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4446-51. PubMed ID: 27044078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions.
    Bozhanova NG; Sangha AK; Sevy AM; Gilchuk P; Huang K; Nargi RS; Reidy JX; Trivette A; Carnahan RH; Bukreyev A; Crowe JE; Meiler J
    Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31142-31148. PubMed ID: 33229516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes.
    Briney BS; Willis JR; Crowe JE
    PLoS One; 2012; 7(5):e36750. PubMed ID: 22590602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.
    Hoffenberg S; Powell R; Carpov A; Wagner D; Wilson A; Kosakovsky Pond S; Lindsay R; Arendt H; Destefano J; Phogat S; Poignard P; Fling SP; Simek M; Labranche C; Montefiori D; Wrin T; Phung P; Burton D; Koff W; King CR; Parks CL; Caulfield MJ
    J Virol; 2013 May; 87(10):5372-83. PubMed ID: 23468492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.
    Willis JR; Sapparapu G; Murrell S; Julien JP; Singh V; King HG; Xia Y; Pickens JA; LaBranche CC; Slaughter JC; Montefiori DC; Wilson IA; Meiler J; Crowe JE
    J Clin Invest; 2015 Jun; 125(6):2523-31. PubMed ID: 25985274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors.
    Willis JR; Berndsen ZT; Ma KM; Steichen JM; Schiffner T; Landais E; Liguori A; Kalyuzhniy O; Allen JD; Baboo S; Omorodion O; Diedrich JK; Hu X; Georgeson E; Phelps N; Eskandarzadeh S; Groschel B; Kubitz M; Adachi Y; Mullin TM; Alavi NB; Falcone S; Himansu S; Carfi A; Wilson IA; Yates JR; Paulson JC; Crispin M; Ward AB; Schief WR
    Immunity; 2022 Nov; 55(11):2149-2167.e9. PubMed ID: 36179689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
    Easterhoff D; Moody MA; Fera D; Cheng H; Ackerman M; Wiehe K; Saunders KO; Pollara J; Vandergrift N; Parks R; Kim J; Michael NL; O'Connell RJ; Excler JL; Robb ML; Vasan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Kepler TB; Alam SM; Liao HX; Ferrari G; Seaman MS; Montefiori DC; Tomaras GD; Harrison SC; Haynes BF
    PLoS Pathog; 2017 Feb; 13(2):e1006182. PubMed ID: 28235027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller.
    Chevigne A; Delhalle S; Counson M; Beaupain N; Rybicki A; Verschueren C; Staub T; Schmit JC; Seguin-Devaux C; Deroo S
    AIDS; 2016 Jan; 30(3):377-82. PubMed ID: 26760231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor.
    Liu L; Wang W; Yang L; Ren H; Kimata JT; Zhou P
    J Virol; 2013 Feb; 87(3):1899-905. PubMed ID: 23152526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.
    Shen G; Upadhyay C; Zhang J; Pan R; Zolla-Pazner S; Kong XP; Hioe CE
    PLoS One; 2015; 10(10):e0141233. PubMed ID: 26491873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120.
    Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA
    Front Immunol; 2018; 9():3163. PubMed ID: 30697215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germlining of the HIV-1 broadly neutralizing antibody domain m36.
    Chen W; Li W; Ying T; Wang Y; Feng Y; Dimitrov DS
    Antiviral Res; 2015 Apr; 116():62-6. PubMed ID: 25676867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.
    Hicar MD; Chen X; Kalams SA; Sojar H; Landucci G; Forthal DN; Spearman P; Crowe JE
    Mol Immunol; 2016 Feb; 70():94-103. PubMed ID: 26748387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.
    Bonsignori M; Wiehe K; Grimm SK; Lynch R; Yang G; Kozink DM; Perrin F; Cooper AJ; Hwang KK; Chen X; Liu M; McKee K; Parks RJ; Eudailey J; Wang M; Clowse M; Criscione-Schreiber LG; Moody MA; Ackerman ME; Boyd SD; Gao F; Kelsoe G; Verkoczy L; Tomaras GD; Liao HX; Kepler TB; Montefiori DC; Mascola JR; Haynes BF
    J Clin Invest; 2014 Apr; 124(4):1835-43. PubMed ID: 24614107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
    Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
    J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
    Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates.
    Steichen JM; Phung I; Salcedo E; Ozorowski G; Willis JR; Baboo S; Liguori A; Cottrell CA; Torres JL; Madden PJ; Ma KM; Sutton HJ; Lee JH; Kalyuzhniy O; Allen JD; Rodriguez OL; Adachi Y; Mullen TM; Georgeson E; Kubitz M; Burns A; Barman S; Mopuri R; Metz A; Altheide TK; Diedrich JK; Saha S; Shields K; Schultze SE; Smith ML; Schiffner T; Burton DR; Watson CT; Bosinger SE; Crispin M; Yates JR; Paulson JC; Ward AB; Sok D; Crotty S; Schief WR
    Science; 2024 May; 384(6697):eadj8321. PubMed ID: 38753769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.
    Pancera M; McLellan JS; Wu X; Zhu J; Changela A; Schmidt SD; Yang Y; Zhou T; Phogat S; Mascola JR; Kwong PD
    J Virol; 2010 Aug; 84(16):8098-110. PubMed ID: 20538861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.